Main Article Content
Public reimbursement, off lable, prescription drugs
Author's response to comments from Dr Lexchin's Letter to the Editor regarding our article.
2. Anti-vascular endothelial growth factor (VEGF) drugs for the treatment of retinal conditions: recommendations report (May 2016). https://www.cadth.ca/sites/default/files/pdf/TR0009_Anti-VEGFs_Recs_Report.pdf (accessed on: November 20, 2018).
3. Lexchin J. Editorial. J Popul Ther Clin Pharmacol 2018;25:e31-2.
4. Avastin Product Monograph (June 6, 2018). http://www.rochecanada.com/content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Avastin/Avastin_PM_E.pdf (accessed on: November 20, 2018).
5. Rawson NSB, Adams J. Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles? Clinicoecon Outcomes Res 2017;9:721-30.